Breaking AI & Tech News Analyzed

The Pavlovian Paradox: Mosquitoes Learn to Associate DEET with FoodFor decades, the efficacy of DEET (N,N-diethyl-meta-toluamide) has been attributed solely to its chemical properties, which are believed to either repel insects or block their ability to detect humans. However, a new study led by Professor Claudio Lazzari from the University of Tours suggests a more complex behavioral interaction. The research indicates that mosquitoes can learn to associate the scent of DEET with the presence of a blood meal, effectively turning a repellent into a lure through a process similar to Pavlovian conditioning.Experimental Evidence: From Repellent to LureThe study, published in the Journal of Experimental Biology, involved trapping mosquitoes and presenting them with warm blood that was just out of reach. The insects were simultaneously exposed to DEET. The results demonstrated a significant shift in behavior:Trained Group: 60% of mosquitoes that fed while exposed to DEET subsequently attempted to bite when exposed to the repellent alone.Control Groups: Significantly lower percentages were observed in untrained insects (17%) and those with prior exposure to DEET alone (13%).In a real-world test, nearly 60% of the trained mosquitoes attempted to bite a researcher's DEET-treated hand, whereas untrained mosquitoes universally targeted the untreated hand.Redefining Insect Control StrategiesThis discovery represents a significant shift in our understanding of how repellents work. It suggests that the reaction to DEET is not merely a chemical aversion but can be modified by experience. Experts, including Dr. Nina Stanczyk of ETH Zürich, emphasize that while the learning ability of mosquitoes is impressive, the implications for public health are nuanced. The study highlights that repellents may function differently depending on the context of the mosquito's previous interactions with humans.Future Outlook for TravelersDespite the alarming findings, experts urge travelers not to abandon DEET. The consensus is that this phenomenon occurs under specific laboratory conditions and is unlikely to happen frequently in the wild due to the variability of repellents encountered during different blood meals. The key takeaway for the future is the importance of consistent application. As noted by the researchers, the risk of association is highest when the repellent starts to wear off, reinforcing the need for regular reapplication to maintain protection.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

Brighton & Hove Albion Women will take the field against Manchester City Women at Wembley on 31 May 2026 for the Women's FA Cup final. City aim to complete a first-ever double, while Brighton chase their inaugural major trophy, playing under the emotional weight of the recent passing of Rado Vidosic, the club’s former head of coaching. Brighton Chasing First Major Trophy Amid Tribute to Late Coach Rado Vidosic The match carries deep personal significance for Brighton. Rado Vidosic, who died from cancer four months earlier, was a pivotal figure in the club’s development. His son, Dario Vidosic, who grew up watching Wembley finals, now leads the team onto the pitch, honoring his father's legacy. Match Timing, Historical Context and Key Figures Kick‑off: 3:00 pm BST (13:00 GMT) City’s ambition: First domestic double in club history. Brighton’s goal: First Women’s FA Cup title since the competition’s inception. Key players: Khadija “Bunny” Shaw (City) – recently secured a four‑year contract extension; Ruth Keenan (Brighton) – leading scorer this season. Historical note: City have won the league this season; Brighton have never lifted the cup. Potential Shift in Women’s Football Power Balance A Brighton victory would signal a breakthrough for clubs outside the traditional powerhouses, potentially encouraging greater investment in smaller teams. Conversely, a City win would cement their dominance and could accelerate the professionalisation of the women's game across England, attracting more sponsors and media attention. What the Result Could Mean for Both Clubs If City wins: Reinforces their status as the premier English women’s side, boosting brand value and likely influencing future player recruitment. If Brighton wins: Provides a morale boost, validates the club’s development pathway, and may spur increased fan engagement and funding. Long‑term outlook: Either outcome will shape the narrative for the 2026‑27 season, affecting league dynamics, TV rights negotiations and grassroots participation.

The Schreiber family, presiding over a nationwide commercial portfolio via the Midos Group, is at the center of a growing controversy involving two distinct business models: aggressive tax avoidance and the profiteering from the UK's housing crisis. The Dual Nature of the Schreiber Business Empire The investigation reveals a complex web of family-owned entities that appear to operate on opposite ends of the social spectrum. On one side, the Midos Group is accused of exploiting a controversial tax scheme to avoid business rates on empty commercial properties. On the other, a similarly named but ostensibly separate entity, Midos Management Co, is profiting from the UK's chronic shortage of social housing by arranging temporary accommodation for homeless residents. Midos Group: Accused of using the 'faith room' scheme to avoid rates on empty units. Midos Management Co: Collecting fees for arranging temporary accommodation for councils. Key Figures: David Schreiber (Midos Group) and Elizabeth Endzweig (Midos Management Co). Financial Impact of the 'Faith Room' Tax Loophole The core of the tax avoidance allegations centers on a provision that exempts property owners from paying business rates if the space is made available for religious worship. The 'faith room' scheme, marketed by Verity, allegedly involves minimal activity—such as placing a notice and a staff member reading scripture—to create the appearance of worship. Total Savings: Landlords have saved at least £18m through this scheme. Specific Case: Dover District Council is suing for £1.7m of unpaid tax. Properties Involved: Discovery Park in Kent and a disused pub in Clapham, London. Profiting from the Homelessness Crisis While the family allegedly avoids taxes on empty buildings, they are simultaneously capitalizing on the housing emergency. Midos Management Co acts as an intermediary, matching councils with private landlords to house homeless residents. Despite claims of separation, evidence suggests significant overlap between the two entities. Revenue Collected: At least £43m collected on behalf of landlords since 2019. Client Base: Lambeth council and at least four other councils. Directorship Overlap: Elizabeth Endzweig, daughter of David Schreiber, is a co-director of multiple companies sharing the same address as Midos Group. The Future of UK Property Tax Compliance The revelations highlight a growing tension between private profit and public service obligations. With MPs and councils increasingly scrutinizing these arrangements, the 'faith room' exemption is likely to face tighter regulatory oversight. The case sets a precedent for how closely connected family businesses can be without violating anti-avoidance rules, potentially leading to stricter audits of corporate structures in the property sector.

The Architecture of an African GiantIn less than two decades, Morocco has redefined African football, evolving from a team frequently eliminated in group stages to a global powerhouse ranked in the top 10 of the FIFA men’s rankings. This meteoric rise is not accidental but the result of a long-term national project initiated by King Mohammed VI in 2008.The success is built on three distinct pillars: good governance, financial investment, and competent human resources. The first step involved creating a national department for financial control to professionalise the federation's structure. This was followed by a massive infrastructure overhaul, including the construction of thousands of 'proximity fields' for mass participation and the Mohammed VI Complex in Maamoura, a technical center often compared to France's elite Clairefontaine academy.A Trophy Cabinet OverflowingThe impact of this strategy is evident in the sheer volume of recent accolades. The Atlas Lions have dominated across every age group, securing titles that span senior, youth, and women's football:2025 AFCON Champions (after Senegal were stripped of the title)2025 WAFCON Finalists2025 FIFA Arab Cup Champions2025 African Nations Championship (CHAN) Champions2025 U-20 FIFA World Cup Champions2025 U-17 AFCON Champions2024 Olympic Men’s Bronze Medallist2024 Futsal AFCON ChampionsThe Diaspora Strategy and Infrastructure BoomA critical factor in Morocco's ascent is the reform of national eligibility rules, which opened the door to players from the European diaspora. This strategy has attracted stars like Hakim Ziyech, Nordin Amrabat, and Brahim Diaz.The latest addition to this lineage is Ayyoub Bouaddi, an 18-year-old Lille midfielder. Despite interest from Zinedine Zidane and the French national team, Bouaddi chose to represent Morocco, highlighting the magnetic pull of the national project. The Mohammed VI Complex has already produced top talent, including Nayef Aguerd, Azzedine Ounahi, and Youssef En-Nesyri.Navigating the 2026 World Cup and the 2030 DreamWith high expectations for the 2026 World Cup in the USA, Canada, and Mexico, Morocco faces a transitional period following the resignation of coach Walid Regragui after the controversial 2025 AFCON final. The federation has appointed Mohamed Ouahbi, who led the youth team to the U-20 World Cup title.While Ouahbi’s more adventurous style differs from Regragui’s pragmatic resilience, the foundation is solid. The world views Morocco as a credible contender, but the team understands that the 2026 tournament is merely a milestone. With Morocco set to co-host the 2030 World Cup alongside Spain and Portugal, the current success is viewed as the acceleration of a broader national development agenda.

The Election Outcome Malta’s Labour Party (PL) has won an unprecedented fourth term in a victory for Prime Minister Robert Abela, according to preliminary results of the election held on Saturday. The party secured a comfortable parliamentary majority, although it appeared to be narrower than in 2022, when it took 55 percent of all ballots cast. Abela's Victory Speech “This is a victory of all the people based on the programme we presented for all the people,” Abela told reporters, saying results showed his party had “won a strong mandate”. He called for national unity, stating, “Let us maintain the spirit of national unity and move the country forward together.” Election Details Election held on Saturday with a turnout of 87.4 percent, slightly up from the last general election in 2022. Abela, 48, called the snap election a year early to shield Malta from geopolitical crises. The economy grew 4 percent last year, but there are concerns about the impact of the Middle East conflict on tourism and inflation. Opposition's Response Charles Bonello, general secretary of the opposition Nationalist Party (PN), conceded the election but noted that his party had managed to slash back Labour’s majority. The Road Ahead Abela has led Malta since 2020. His government will continue to focus on economic stability and addressing challenges such as corruption, which remains a significant issue in the country.

Sky announced it will exit its 24‑hour Arabic news joint venture with the United Arab Emirates, Sky News Arabia, following intense criticism over the channel’s coverage of the Sudan war and accusations of genocide denial. Under a new commercial agreement, Sky will give up all strategic and operational control but will continue to license the Sky News brand to the outlet. Strategic Withdrawal and New Licensing Arrangement The exit sees Sky handing over full ownership to IMI, the investment vehicle controlled by Sheikh Mansour bin Zayed al‑Nahyan, UAE vice‑president and Manchester City owner. In a statement, David Rhodes, executive chairman of Sky News Group, said the partnership had built a significant regional presence and that the timing was right for a change. IMI will now steer the platform’s future, while Sky secures a multi‑year brand‑licensing deal that lets the channel retain the Sky News Arabia name. Timeline of Sky News Arabia’s Decade‑Long Presence 2010: Channel launched in Abu Dhabi as a rival to Al‑Jazeera and BBC Arabic. 2012: Joint venture began broadcasting across the Middle East and North Africa. November 2025: Sudanese government banned the channel after a report claimed stability in El Fasher. February 2026: UN fact‑finding mission identified “hallmarks of genocide” in the RSF siege of El Fasher. May 2026: Sky announces exit and new licensing deal. Reputational and Regional Implications of the Sudan Coverage Controversy Internal Sky executives grew uneasy about the editorial line taken by Sky News Arabia, which was accused of whitewashing atrocities committed by the UAE‑backed Rapid Support Forces (RSF). Specific concerns included a report that downplayed the humanitarian crisis and the fact that the channel’s reporter in El Fasher was married to a senior RSF official. The controversy prompted Sudan to ban the channel and heightened scrutiny of the venture’s credibility across the Arab world. Future Outlook for Sky’s Middle‑East Footprint Nakhle ElHage, chief transformation officer at IMI, said the next phase will focus on building the platform into the leading multi‑media news destination for the Arab world. For Sky, the move mirrors a similar decision in Australia, where a licensing agreement for the Sky News brand is ending and the channel will rebrand as News24. The brand‑licensing arrangement allows Sky to maintain a presence without direct editorial responsibility, while IMI gains full control to shape content and investment strategy.

Donald Trump told Fox News he is in no hurry to finalize a nuclear deal with Iran as Israeli forces deepened their ground incursion in southern Lebanon, marking day 93 of the regional war. The statements came alongside reports of a captured strategic castle, new Iranian naval capabilities, and a draft memorandum that would release $12 billion in frozen Iranian assets.Intensifying Ground Operations: Israel Captures Beaufort CastleIsraeli troops seized the historic Beaufort Castle (Qalaat al‑Shaqif) near Nabatieh, the deepest Israeli advance in 26 years.The Israeli military warned residents south of the Zahrani River to evacuate and launched large‑scale operations across the Beaufort Ridge and Wadi al‑Salouqi.Air raids hit Arnoun, Kfar Tebnit, Kfar Remman, Kfarjouz and Dbeibine, while a 21‑year‑old Israeli soldier was killed and four wounded.Lebanon’s Prime Minister Nawaf Salam condemned what he called a “scorched‑earth policy” as forces push toward Nabatieh.Financial Stakes: $12 Billion Frozen Iranian Assets in Draft DealIranian state media cited an “unofficial” memorandum that would free $12 billion of Iranian assets frozen by the United States.U.S. officials reported that President Trump requested several amendments to the preliminary agreement during a White House Situation Room meeting.Congress advanced a U.S.–Israeli military integration plan, potentially deepening joint weapons research and production.Regional Ramifications: Heightened Tensions Across the Middle EastIran’s IRGC claimed to have shot down a U.S. drone and unveiled a new naval attack craft capable of 100 knots, signaling a rapid military modernization.The United States disabled a Gambia‑flagged vessel attempting to reach an Iranian port, prompting Tehran to accuse Washington of “betraying diplomacy.”Rear Admiral Habibollah Sayyari warned that any further aggression would meet an even stronger response.Israel’s expanded forward‑defense line now crosses the Litani River, tightening the front against Hezbollah.What Lies Ahead: Prospects for U.S.–Iran Negotiations and Regional StabilityTrump’s “no rush” stance suggests the nuclear framework will be refined before any release of assets, potentially extending negotiations into late 2026.Continued Israeli advances risk drawing Hezbollah into a broader ground conflict, which could pressure the U.S. to reassess its diplomatic leverage.The new U.S.–Israeli integration plan may lock Washington into a tighter security partnership, influencing future policy toward Iran.Analysts warn that without a clear de‑escalation path, the war’s 93‑day trajectory could expand beyond Lebanon, affecting regional energy markets and global diplomatic efforts.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."